Strategic Partnerships OncoDNA has a history of milestone partnerships with leading oncology organizations and has an international distribution network. This indicates high potential for channel partnerships, co-marketing opportunities, and joint development programs with diagnostic labs, pharma companies, and academic centers.

Liquid Biopsy Expansion Recent launch of fragmentomics liquid biopsy assay and planned rollout across Europe and other markets creates a sales opening for companion diagnostic discussions, clinical trial support, and routine monitoring programs using minimally invasive biomarker testing.

New Product Pipeline Upcoming OncoXPLORE tumor-naïve molecular profiling and the existing OncoDeep kit signal a broadening product suite. This presents cross-sell opportunities to existing customers and interest from research labs and hospitals seeking comprehensive genomic solutions.

Clinical Decision Support The company combines NGS services with data analysis software and clinical decision support tools. There is a strong use case for selling integrated software licenses, data analytics subscriptions, and value-based services to oncology clinics aiming to optimize therapy decisions.

Global Growth Signals With headquarters in Belgium, entities in Spain and France, and an international distributor network, OncoDNA is positioned for cross-border sales, market entry partnerships, and regional expansions in Europe and beyond, appealing to distributors, CROs, and hospital networks seeking scalable precision medicine solutions.